PDF(Pubmed)
Abstract：
The objective of this article was to provide an overview of the development and recommendations from the Australian evidence-based clinical practice guideline for attention deficit hyperactivity disorder (ADHD). The guideline aims to promote accurate and timely identification and diagnosis, and optimal and consistent treatment of ADHD.
Development integrated the best available evidence with multidisciplinary clinical expertise and the preferences of those with lived experience, underpinned by the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) framework. The 23 guideline development group members included psychiatrists, paediatricians, general practitioners, psychologists, speech pathologists, occupational therapists, educators, Indigenous psychologists, and people with a lived experience; with two independent chairs and a methodologist. Where appropriate, evidence reviews from the National Institute for Health and Care Excellence (NICE) 2018 \'Attention Deficit Hyperactivity Disorder: Diagnosis and Management\' guideline were updated. Fifty prioritised clinical questions were addressed in 14 systematic reviews (new and updated from NICE 2018) and 28 narrative reviews.
The 113 clinical recommendations apply to young children (5 years and under), children, adolescents and adults. They provide guidance for clinicians on identification, screening, diagnosis, multimodal treatment and support, including pharmacological and non-pharmacological interventions. The guideline and supporting information are available online: https://adhdguideline.aadpa.com.au/.
The guideline was approved by the National Health and Medical Research Council (NHMRC) of Australia and relevant medical and allied health professional associations. It is anticipated that successful implementation and uptake of the guideline by organisations, health care providers and other professionals will increase delivery of evidence-based treatment and improve health outcomes for the more than 800,000 Australians with ADHD.
Development integrated the best available evidence with multidisciplinary clinical expertise and the preferences of those with lived experience, underpinned by the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) framework. The 23 guideline development group members included psychiatrists, paediatricians, general practitioners, psychologists, speech pathologists, occupational therapists, educators, Indigenous psychologists, and people with a lived experience; with two independent chairs and a methodologist. Where appropriate, evidence reviews from the National Institute for Health and Care Excellence (NICE) 2018 \'Attention Deficit Hyperactivity Disorder: Diagnosis and Management\' guideline were updated. Fifty prioritised clinical questions were addressed in 14 systematic reviews (new and updated from NICE 2018) and 28 narrative reviews.
The 113 clinical recommendations apply to young children (5 years and under), children, adolescents and adults. They provide guidance for clinicians on identification, screening, diagnosis, multimodal treatment and support, including pharmacological and non-pharmacological interventions. The guideline and supporting information are available online: https://adhdguideline.aadpa.com.au/.
The guideline was approved by the National Health and Medical Research Council (NHMRC) of Australia and relevant medical and allied health professional associations. It is anticipated that successful implementation and uptake of the guideline by organisations, health care providers and other professionals will increase delivery of evidence-based treatment and improve health outcomes for the more than 800,000 Australians with ADHD.
摘要：
■本文的目的是概述澳大利亚基于证据的注意缺陷多动障碍（ADHD）临床实践指南的发展和建议。该指南旨在促进准确和及时的识别和诊断，和多动症的最佳和一致的治疗。
■开发将现有的最佳证据与多学科临床专业知识以及有经验的人的偏好相结合，以建议分级为基础，评估,发展,和评估（等级）框架。23个指南发展小组成员包括精神科医生，儿科医生,全科医生,心理学家,言语病理学家，职业治疗师,教育工作者,土著心理学家,和有生活经验的人；有两个独立的椅子和一个方法学家。在适当的情况下，美国国家健康与护理卓越研究所(NICE)2018年的“注意力缺陷多动障碍:诊断和管理”指南的证据综述已更新.在14项系统评价（NICE2018年新增和更新）和28项叙述性评价中解决了50个优先临床问题。
■113项临床建议适用于幼儿（5岁及以下），孩子们,青少年和成年人。他们为临床医生提供识别指导，筛选,诊断,多模式治疗和支持，包括药物和非药物干预措施。指南和支持信息可在线获得：https://adhdguideline。aadpa.com.au/.
■该指南得到了澳大利亚国家卫生与医学研究委员会（NHMRC）以及相关医学和相关卫生专业协会的批准。预计组织将成功实施和采纳该指南，医疗保健提供者和其他专业人员将增加循证治疗的交付，并改善80多万患有ADHD的澳大利亚人的健康结果。
■开发将现有的最佳证据与多学科临床专业知识以及有经验的人的偏好相结合，以建议分级为基础，评估,发展,和评估（等级）框架。23个指南发展小组成员包括精神科医生，儿科医生,全科医生,心理学家,言语病理学家，职业治疗师,教育工作者,土著心理学家,和有生活经验的人；有两个独立的椅子和一个方法学家。在适当的情况下，美国国家健康与护理卓越研究所(NICE)2018年的“注意力缺陷多动障碍:诊断和管理”指南的证据综述已更新.在14项系统评价（NICE2018年新增和更新）和28项叙述性评价中解决了50个优先临床问题。
■113项临床建议适用于幼儿（5岁及以下），孩子们,青少年和成年人。他们为临床医生提供识别指导，筛选,诊断,多模式治疗和支持，包括药物和非药物干预措施。指南和支持信息可在线获得：https://adhdguideline。aadpa.com.au/.
■该指南得到了澳大利亚国家卫生与医学研究委员会（NHMRC）以及相关医学和相关卫生专业协会的批准。预计组织将成功实施和采纳该指南，医疗保健提供者和其他专业人员将增加循证治疗的交付，并改善80多万患有ADHD的澳大利亚人的健康结果。
